2024-04-30 12:47:04 ET
Summary
- Biogen Inc.'s Alzheimer therapy, Leqembi, is finally gaining traction with Q1 '24 sales of $19 million, nearly tripling Q4 revenues.
- The drug has faced challenges in gaining coverage and reimbursement, but it is expected to reach multi-billion dollar sales levels by decade's end.
- Biogen's overall sales have been declining, but the combination of Leqembi and other new drugs could help stem the decline and lead to sales growth by the end of 2024.
- The stock only trades at 12x '25 EPS targets based on conservative sales estimates.
Biogen Inc. ( BIIB ) just reported a quarter where their Alzheimer's therapy is finally gaining traction. The stock has only made a slight bounce off the bottom, providing the opportunity to jump onto the story for a stock that topped $300 last year. My investment thesis remains Bullish on the stock due to valuation and this potential drug catalyst finally materializing....
Read the full article on Seeking Alpha
For further details see:
Biogen: Don't Overthink This One